DiscoverSpeaking of Mol BioTherapeutic nucleic acids – a CDMO’s view on mRNA
Therapeutic nucleic acids – a CDMO’s view on mRNA

Therapeutic nucleic acids – a CDMO’s view on mRNA

Update: 2024-09-15
Share

Description

While some of us knew a good bit about mRNA prior to 2020, we all got a crash course on mRNA technology and its prophylactic and therapeutic potential as a result of the COVID pandemic and subsequent SARS CoV-2 vaccine development. In fact, most of us have now received at least one mRNA vaccine at this point.

Our guest for this episode, Dr. Christian Cobaugh, Co-founder and CEO of Vernal Biosciences, was a passionate believer in mRNA medicines well before the pandemic. Join us to hear his story and his passion for this technology. He walks us through the molecular methods by which high-purity mRNAs are now made and purified, as well as going into the lipid nanoparticle technology by which they’re commonly delivered. As a contract development and manufacturing provider, we get to learn about the state of the market and what clients of their care about today. As a seasoned expert in this space, Christian talks about the future potential of mRNA technology for applications such as personalized cancer vaccines.

If you enjoy hearing smart people talk about interesting topics with a passion, you won’t want to miss this episode!


Subscribe to get future episodes as they drop and if you like what you’re hearing we hope you’ll share a review or recommend the series to a colleague. 

 

Download Transcripts: 

Speaking of Mol Bio Podcast | Thermo Fisher Scientific - US

 

Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. 

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Therapeutic nucleic acids – a CDMO’s view on mRNA

Therapeutic nucleic acids – a CDMO’s view on mRNA

Thermo Fisher Scientific